1342.4 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Page last updated: 29 September 2017

Application Detail

Status

Open

Description of Medical Service

Oncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

1342.3

Associated Documentation

Application Form

-

PICO Confirmation

As per application 1342

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 445 KB)
Public Summary Document (Word 104 KB)

Meetings for this Application

PASC

-

ESC

8 June 2017

MSAC

27 July 2017